Vital Signs - Contract Research and Manufacturing Services: Best Practices, Investment Strategy and Deal-Making

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on April 6, 2010, provides a strategic overview of current trends and issues impacting contract research and manufacturing in the pharma & biotech industry. Additionally, a company spotlight is provided for Vaccinogen, a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. Reimbursement and regulatory news from the FDA is also provided for the week of March 15, 2010.

Table of Contents

Vital Signs - Contract Research and Manufacturing Services: Best Practices, Investment Strategy and Deal-MakingVital Signs: 5 April 2010This week's issue:




Related Research

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.